Novel therapies in myeloma

Current Opinion in Hematology

Volumn 14, Issue 6, 2007, Pages 609-615

  Hayden, Patrick J ^a   Mitsiades, Constantine S ^a   Anderson, Kenneth C ^a   Richardson, Paul G ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Bortezomib; Immunomodulatory; Myeloma; Targeted therapy

Indexed keywords

17 AAG; 3 (4 AMINO 1,3 DIHYDRO 1,3 DIOXO 2H ISOINDOL 2 YL)GLUTARIMIDE; ARSENIC TRIOXIDE; BORTEZOMIB; CYCLOPHOSPHAMIDE; DEFIBROTIDE; DEXAMETHASONE; DOXORUBICIN; HEAT SHOCK PROTEIN 90 INHIBITOR; HISTONE DEACETYLASE INHIBITOR; LBH 589; LENALIDOMIDE; MELPHALAN; PREDNISOLONE; PREDNISONE; THALIDOMIDE; UNCLASSIFIED DRUG; VINCRISTINE; VORINOSTAT;

ADD ON THERAPY; BIOLOGY; BLEEDING; BONE MARROW SUPPRESSION; CHROMOSOME DELETION 13; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; DEEP VEIN THROMBOSIS; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG USE; FATIGUE; GASTROINTESTINAL SYMPTOM; HUMAN; LOW DRUG DOSE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MYELOMA; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; REVIEW; SEDATION; SIDE EFFECT; THROMBOCYTOPENIA;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MULTIPLE MYELOMA; PYRAZINES; THALIDOMIDE;

EID: 34848845570     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0b013e3282f0e948     Document Type: Review

References (72)

1. Anderson KC. New drugs for multiple myeloma. Clin Adv Hematol Oncol 2006; 4:592-594.
2. Orlowski RZ. Initial therapy of multiple myeloma patients who are not candidates for stem cell transplantation. Hematology Am Soc Hematol Educ Program 2006; 338-347.
3. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin 2007; 57:43-66.
4. Fonseca R, Blood E, Rue M, et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood 2003; 101:4569-4575.
5. Dispenzieri A, Rajkumar SV, Gertz MA, et al. Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement. Mayo Clinic Proc 2007; 82:323-341.
6. Hideshima T, Mitsiades C, Tonon G, et al. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer 2007; 7:585-598. This is a comprehensive review on the therapeutic relevance of tumor-stromal interactions in multiple myeloma.
7. Pant S, Copelan EA. Hematopoietic stem cell transplantation in multiple myeloma. Biol Blood Marrow Transplant 2007; 13:877-885.
8. Attal M, Harousseau JL, Facon T, et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003; 349:2495-2502.
9. Bruno B, Rotta M, Patriarca F, et al. A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med 2007; 356:1110-1120.
10. Moehler TM, Hillengass J, Glasmacher A, Goldschmidt H. Thalidomide in multiple myeloma. Curr Pharm Biotechnol 2006; 7:431-440.
11. Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341:1565-1571.
12. Prince HM, Honemann D, Spencer A, et al. VEGF-R inhibition with pazopanib (GW786034) is ineffective in pretreated myeloma. Haematologica 2007; 92:153.
13. Palumbo A, Giaccone L, Bertola A, et al. Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma. Haematologica 2001; 86:399-403.
14. Dimopoulos MA, Zervas K, Kouvatseas G, et al. Thalidomide and dexamethasone combination for refractory multiple myeloma. Ann Oncol 2001; 12:991-995.
15. Terpos E, Mihou D, Szydlo R, et al. The combination of intermediate doses of thalidomide with dexamethasone is an effective treatment for patients with refractory/relapsed multiple myeloma and normalizes abnormal bone remodeling, through the reduction of sRANKL/osteoprotegerin ratio. Leukemia 2005; 19:1969-1976.
16. Murakami H, Handa H, Abe M, et al. Low-dose thalidomide plus low-dose dexamethasone therapy in patients with refractory multiple myeloma. Eur J Haematol 2007; 26 Jul [Epub ahead of print].
17. Kyriakou C, Thomson K, D'Sa S, et al. Low-dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma. Br J Haematol 2005; 129:763-770.
18. Garcia-Sanz R, Gonzalez-Porras JR, Hernandez JM, et al. The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed/refractory multiple myeloma. Leukemia 2004; 18:856-863.
19. Offidani M, Bringhen S, Corvatta L, et al. Thalidomide- dexamethasone plus pegylated liposomal doxorubicin vs. thalidomide- dexamethasone: a case-matched study in advanced multiple myeloma. Eur J Haematol 2007; 78:297-302.
20. Rajkumar SV, Hayman S, Gertz MA, et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 2002; 20:4319-4323.
21. Weber D, Rankin K, Gavino M, et al. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 2003; 21:16-19.
22. Cavo M, Zamagni E, Tosi P, et al. First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma. Haematologica 2004; 89:826-831.
23. Rajkumar SV, Blood E, Vesole D, et al. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2006; 24:431-436. This phase III trial confirmed the superiority of thalidomide-dexamethasone versus dexamethasone alone in newly diagnosed multiple myeloma.
24. Richardson P, Anderson K. Thalidomide and dexamethasone: a new standard of care for initial therapy in multiple myeloma. J Clin Oncol 2006; 24:334-336.
25. Zervas K, Dimopoulos MA, Hatzicharissi E, et al. Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): a phase II multicenter study. Ann Oncol 2004; 15:134-138.
26. Offidani M, Corvatta L, Piersantelli MN, et al. Thalidomide, dexamethasone, and pegylated liposomal doxorubicin (ThaDD) for patients older than 65 years with newly diagnosed multiple myeloma. Blood 2006; 108:2159-2164.
27. Wu P, Davies FE, Horton C, et al. The combination of cyclophosphomide, thalidomide and dexamethasone is an effective alternative to cyclophosphamide-vincristine-doxorubicin-methylprednisolone as induction chemotherapy prior to autologous transplantation for multiple myeloma: a case-matched analysis. Leuk Lymphoma 2006; 47:2335-2338.
28. Dimopoulos MA, Anagnostopoulos A, Terpos E, et al. Primary treatment with pulsed melphalan, dexamethasone and thalidomide for elderly symptomatic patients with multiple myeloma. Haematologica 2006; 91:252-254.
29. Palumbo A, Bringhen S, Caravita T, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 2006; 367:825-831. This phase III trial documents that the oral combination of melphalan-prednisone-thalidomide is an effective first-line treatment for elderly multiple myeloma patients.
30. Facon T, Mary J, Harousseau J, et al. Superiority of melphalan-prednisone (MP) plus thalidomide (THAL) over MP and autologous stem cell transplantation in the treatment of newly diagnosed elderly patients with multiple myeloma [abstract]. J Clin Oncol 2006 (Suppl 18); 24:1.
31. Barlogie B, Tricot G, Anaissie E, et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med 2006; 354:1021-1030.
32. Attal M, Harousseau JL, Leyvraz S, et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 2006; 108:3289-3294. This randomized trial showed that thalidomide is an effective postransplant maintenance therapy.
33. Martino M, Console G, Callea V, et al. Low tolerance and high toxicity of thalidomide as maintenance therapy after double autologous stem cell transplant in multiple myeloma patients. Eur J Haematol 2007; 78:35-40.
34. Mileshkin L, Stark R, Day B, et al. Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring. J Clin Oncol 2006; 24:4507-4514.
35. Zonder JA. Thrombotic complications of myeloma therapy. Hematology Am Soc Hematol Educ Program 2006; 348-355.
36. El Accaoui RN, Shamseddeen WA, Taher AT. Thalidomide and thrombosis. A meta-analysis. Thromb Haemost 2007; 97:1031-1036.
37. Richardson PG, Mitsiades C, Hideshima T, Anderson KC. Lenalidomide in multiple myeloma. Expert Rev Anticancer Ther 2006; 6:1165-1173.
38. Richardson PG, Blood E, Mitsiades CS, et al. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood 2006; 108:3458-3464. This randomized phase II study showed that lenalidomide is active and well tolerated in relapsed, refractory myeloma, as monotherapy and combined with dexamethasone.
39. Morgan GJ, Schey SA, Wu P, et al. Lenalidomide (Revlimid), in combination with cyclophosphamide and dexamethasone (RCD), is an effective and tolerated regimen for myeloma patients. Br J Haematol 2007; 137:268-269.
40. Baz R, Walker E, Karam MA, et al. Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy. Ann Oncol 2006; 17:1766-1771.
41. Rajkumar SV, Hayman SR, Lacy MQ, et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 2005; 106:4050-4053.
42. Rajkumar SV, Blood E. Lenalidomide and venous thrombosis in multiple myeloma. N Engl J Med 2006; 354:2079-2080.
43. Mitsiades CS, Mitsiades N, Hideshima T, et al. Proteasome inhibition as a new therapeutic principle in hematological malignancies. Curr Drug Targets 2006; 7:1341-1347.
44. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348:2609-2617.
45. Richardson PG, Barlogie B, Berenson J, et al. Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma. Blood 2005; 106:2977-2981.
46. Jagannath S, Barlogie B, Berenson J, et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 2004; 127:165-172.
47. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352:2487-2498.
48. Richardson P, Sonneveld P, Schuster M, et al. Bortezomib continues to demonstrate superior efficacy compared with high-dose dexamethasone in relapsed multiple myeloma: Updated results of the APEX trial. Blood 2005; 106:715A-716A.
49. Richardson PG, Sonneveld P, Schuster MW, et al. Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma. Br J Haematol 2007; 137:429-435.
50. Davies FE, Wu P, Jenner M, et al. The combination of cyclophosphamide, velcade and dexamethasone induces high response rates with comparable toxicity to velcade alone and velcade plus dexamethasone. Haematologica 2007; 92:1149-1150.
51. Kropff M, Bisping G, Liebisch P, et al. Bortezomib in combination with high-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma [abstract]. Blood 2005; 106:716a.
52. Biehn SE, Moore DT, Voorhees PM, et al. Extended follow-up of outcome measures in multiple myeloma patients treated on a phase I study with bortezomib and pegylated liposomal doxorubicin. Ann Hematol 2007; 86:211-216.
53. Orlowski RZ, Zhuang SH, Parekh T, et al. The combination of pegylated liposomal doxorubicin and bortezomib significantly improves time to progression of patients with relapsed/refractory multiple myeloma compared with bortezomib alone: Results from a planned interim analysis of a randomized phase III study [abstract]. Blood 2006; 108:124a.
54. Richardson PG, Jagannath S, Avigan DE, et al. Lenalidomide plus bortezomib (Rev-Vel) in relapsed and/or refractory multiple myeloma (MM): Final results of a multicenter phase 1 trial [abstract]. Blood 2006; 108:124a.
55. Wang M, Giralt S, Delasalle K, et al. Bortezomib in combination with thalidomide-dexamethasone for previously untreated multiple myeloma. Hematology 2007; 12:235-239.
56. Palumbo A, Ambrosini MT, Benevolo G, et al. Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma. Blood 2007; 109:2767-2772. This describes a multicenter phase I/II trial of the 4-drug combination, bortezomib, melphalan, prednisone, and thalidomide (VMPT).
57. Anderson K, Richardson P, Chanan-Khan A, et al. Single-agent bortezomib in previously untreated multiple myeloma (MM): Results of a phase II multicenter study [abstract]. J Clin Oncol 2006 (Suppl); 24:423.
58. Jagannath S, Durie BG, Wolf J, et al. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol 2005; 129:776-783.
59. Harousseau JL, Attal M, Leleu X, et al. Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study. Haematologica 2006; 91:1498-1505.
60. Oakervee HE, Popat R, Curry N, et al. PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br J Haematol 2005; 129:755-762.
61. Mateos MV, Hernandez JM, Hernandez MT, et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study. Blood 2006; 108:2165-2172.
62. Barlogie B, Anaissie E, van Rhee F, et al. Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. Br J Haematol 2007; 138:176-185.
63. Richardson PG, Briemberg H, Jagannath S, et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 2006; 24:3113-3120.
64. Lonial S, Waller EK, Richardson PG, et al. Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. Blood 2005; 106:3777-3784.
65. Anderson KC. Targeted therapy of multiple myeloma based upon tumor-microenvironmental interactions. Exp Hematol 2007; 35 (4 Suppl 1):155-162.
66. Anderson KC, Hannah AL, Pazdur R, Farrell AT. A strategic framework for novel drug development in multiple myeloma. Br J Haematol 2007; 138:153-159.
67. Kalmadi SR, Hussein MA. The emerging role of arsenic trioxide as an immunomodulatory agent in the management of multiple myeloma. Acta Haematol 2006; 116:1-7.
68. Mitsiades CS, Mitsiades NS, McMullan CJ, et al. Antimyeloma activity of heat shock protein-90 inhibition. Blood 2006; 107:1092-1100. These preclinical studies provided the rationale for clinical testing of hsp90 inhibitors in multiple myeloma.
69. Maiso P, Carvajal-Vergara X, Ocio EM, et al. The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance. Cancer Res 2006; 66:5781-5789.
70. Mitsiades CS, Rouleau C, Menon K, et al. Defibrotide (DF) targets tumor-microenvironmental interactions and sensitizes multiple myeloma and solid tumor cells to cytotoxic chemotherapeutics [abstract]. Blood 2004; 104:85a.
71. Mitsiades C, Benimetskaya L, Menon K, et al. Defibrotide, an orally bioavailable modulator of myeloma tumor-microenvironment interactions: molecular sequelae and clinical implications [abstract]. Blood 2006; 108:3523a.
72. Palumbo A, Larocca A, Rus C, et al. Efficacy and safety of melphalan, prednisone,thalidomide and defibrotide in relapsed and refractory multiple myeloma patients: Results of a multicenter phase I/II trial. Haematologica 2007; 92:94a.